Many people searching for weight loss solutions encounter references to "Hers weight loss pills." Hers is a US telehealth platform, not a UK prescribing service. In the UK, prescription weight loss medications—primarily GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), or orlistat—are available through regulated online healthcare services. Most GLP-1 treatments are injections, not pills. These medications work by different mechanisms: GLP-1 agonists mimic a natural hormone that regulates appetite, whilst orlistat reduces dietary fat absorption. All prescription weight loss treatments must be prescribed by UK-registered healthcare professionals following proper medical assessment and are intended as part of a comprehensive weight management programme, not standalone solutions.

What Are Hers Weight Loss Pills?

Hers is a telehealth platform originating in the United States. It is not a UK prescribing service. In the UK, when people refer to "Hers weight loss pills," they typically mean prescription weight loss medications that may be accessed through UK-regulated online healthcare services operating under similar models.

The most commonly prescribed medications through such platforms include GLP-1 receptor agonists (such as semaglutide and liraglutide) and orlistat. It is important to note that most GLP-1 treatments for weight management are injections, not pills. Semaglutide (Wegovy) is given as a once-weekly injection, and liraglutide (Saxenda) is a daily injection. Oral semaglutide (Rybelsus) is not licensed for weight management in the UK.

GLP-1 agonists work by mimicking a naturally occurring hormone called glucagon-like peptide-1, which regulates appetite and food intake. These medications slow gastric emptying, increase feelings of fullness, and reduce hunger signals in the brain. Treatment involves a dose-escalation phase to minimise side effects. Semaglutide, marketed as Wegovy for weight management, has gained particular attention for its efficacy in clinical trials.

Orlistat works through a different mechanism entirely. It inhibits pancreatic and gastric lipases—enzymes responsible for breaking down dietary fats—thereby reducing fat absorption in the intestine by approximately 30%. This unabsorbed fat is then excreted, which can lead to weight loss when combined with a reduced-calorie diet. Orlistat is taken with meals containing fat; if a meal is missed or contains no fat, the dose should be skipped.

In the UK, GLP-1 receptor agonists are prescription-only medicines, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Orlistat 120 mg (Xenical) is also prescription-only, but orlistat 60 mg (alli) is available from pharmacies without a prescription following a consultation with a pharmacist. Any legitimate online service offering prescription weight loss medications must operate within UK regulatory frameworks, including registration with the Care Quality Commission (CQC) and the General Pharmaceutical Council (GPhC), and must use UK-registered prescribers (GMC, NMC, or GPhC). Proper medical assessment, prescribing, and monitoring are essential. Weight loss medications are intended as part of a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural support—not as standalone solutions.

Clinical Evidence: Do Hers Weight Loss Pills Work?

The effectiveness of prescription weight loss medications depends entirely on which specific medication is prescribed and how it is used. Clinical evidence for GLP-1 receptor agonists is substantial and well-established. Semaglutide (Wegovy), when used at the 2.4 mg weekly dose for weight management, has demonstrated significant efficacy in large-scale randomised controlled trials. The STEP trial programme (which primarily enrolled adults without type 2 diabetes) showed that participants with obesity achieved an average weight loss of approximately 15% of their initial body weight over 68 weeks, compared to 2.4% with placebo—all participants also received lifestyle intervention. Outcomes may vary in people with type 2 diabetes.

Similarly, liraglutide (Saxenda) has shown meaningful weight reduction in clinical studies. The SCALE trial demonstrated an average weight loss of 8% over 56 weeks in adults with obesity, compared to 2.6% with placebo. Both medications have been evaluated by the National Institute for Health and Care Excellence (NICE). NICE recommends GLP-1 agonists for weight management in specific circumstances: for adults with at least one weight-related comorbidity and a BMI of 35 kg/m² or above (or 32.5 kg/m² or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds). Importantly, NICE specifies that these treatments should be provided within a specialist weight management service with multidisciplinary support and are typically time-limited to up to 2 years. Licensed indications may differ from NICE commissioning criteria, which can affect NHS access.

Orlistat has more modest effects. Clinical trials show an average additional weight loss of 2–3 kg compared to diet and exercise alone over one year. NICE guidance supports orlistat use as part of a comprehensive weight management programme for adults with a BMI of 28 kg/m² or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m² or above without additional risk factors. Treatment should be reviewed at 12 weeks and continued only if adequate weight loss has been achieved (typically at least 5% of initial body weight; a lower threshold may apply in people with type 2 diabetes).

Crucially, all these medications work best when combined with lifestyle modifications. They are not "magic pills" but pharmacological tools that support behaviour change. Weight regain commonly occurs if medication is stopped without maintained lifestyle changes. The evidence clearly demonstrates efficacy, but real-world effectiveness depends on adherence, appropriate patient selection, ongoing support, and integration with dietary and activity interventions. Individual responses vary considerably, and not everyone achieves the average weight loss seen in clinical trials. Before starting pharmacotherapy, healthcare professionals should assess for secondary causes of obesity and exclude active eating disorders.

Who Can Use Hers Weight Loss Treatment in the UK?

Prescription weight loss medications in the UK are not suitable for everyone and have specific eligibility criteria based on NICE guidance and MHRA licensing. Healthcare professionals must conduct a thorough assessment before prescribing these treatments.

Eligibility criteria for GLP-1 receptor agonists are defined by NICE technology appraisals. These treatments should be offered to adults who meet all of the following:

• At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)

• BMI of 35 kg/m² or above (or 32.5 kg/m² or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds)

• Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions

• Treatment is typically time-limited to up to 2 years

• Previous unsuccessful attempts at weight loss through lifestyle measures alone

Orlistat may be considered for adults with a BMI of 28 kg/m² or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m² or above without additional risk factors. Treatment should be reviewed at 12 weeks and continued only if adequate weight loss has been achieved (typically at least 5% of initial body weight; a lower threshold may apply in people with type 2 diabetes).

Important contraindications and cautions exist for all weight loss medications. GLP-1 agonists are contraindicated in pregnancy. UK Summaries of Product Characteristics (SmPCs) advise caution in people with a history of pancreatitis, severe gastrointestinal disease, or thyroid disease; clinical judgement is required. In people with type 2 diabetes, rapid glycaemic improvement with semaglutide has been associated with worsening diabetic retinopathy, and monitoring may be needed. Orlistat should not be used during pregnancy or in people with chronic malabsorption syndrome or cholestasis.

Legitimate UK-based telehealth services must conduct proper medical assessments, including medical history, current medications, and contraindications screening. Services should be registered with the Care Quality Commission (CQC), use a General Pharmaceutical Council (GPhC)-registered pharmacy, and employ UK-registered prescribers (GMC, NMC, or GPhC). Prescribing without adequate assessment is unsafe and potentially unlawful. Patients should be wary of services that offer these medications without thorough evaluation or appropriate ongoing monitoring. Regular follow-up is essential to assess response, manage side effects, and provide continued lifestyle support.

Potential Side Effects and Safety Considerations

All prescription weight loss medications carry potential side effects, and patients must be fully informed before starting treatment. The side effect profile varies depending on the specific medication prescribed.

GLP-1 receptor agonists (semaglutide, liraglutide) commonly cause gastrointestinal side effects, particularly during dose escalation. These include:

• Nausea (affecting 20–40% of users, usually improving over time)

• Vomiting, diarrhoea, and constipation

• Abdominal pain and bloating

• Reduced appetite (intended effect, but can be excessive)

Less common but more serious adverse effects include pancreatitis (inflammation of the pancreas), gallbladder problems including gallstones, and hypoglycaemia (particularly in people also taking diabetes medications). There have been reports of increased heart rate in some patients. Severe gastrointestinal symptoms can lead to dehydration and acute kidney injury; patients should maintain adequate hydration and seek prompt medical review if they experience reduced urine output or persistent vomiting or diarrhoea. Patients should seek immediate medical attention if they experience severe, persistent abdominal pain, as this may indicate pancreatitis.

Orlistat causes different side effects related to its mechanism of reducing fat absorption:

• Oily spotting and flatulence

• Urgent bowel movements and faecal incontinence

• Oily or fatty stools

These effects are typically worse when consuming high-fat meals and can be socially distressing. Orlistat may also reduce absorption of fat-soluble vitamins (A, D, E, K), so supplementation may be recommended. Multivitamins should be taken at bedtime or at least 2 hours after orlistat. Rarely, orlistat has been associated with severe liver injury; patients should stop treatment and seek medical advice immediately if they develop jaundice, dark urine, itching, or right upper quadrant pain.

Important drug interactions with orlistat include:

• Ciclosporin: orlistat reduces ciclosporin levels; avoid concomitant use or separate doses by at least 3 hours and monitor ciclosporin levels closely

• Warfarin and other anticoagulants: orlistat may affect vitamin K absorption, altering INR; monitor INR closely

• Levothyroxine: orlistat may reduce levothyroxine absorption; separate doses by at least 4 hours and monitor thyroid function

• Potential effects on anticonvulsants and amiodarone should also be considered

Important safety advice includes:

• Report severe or persistent side effects to your prescriber immediately

• Contact your GP urgently if you experience severe abdominal pain, persistent vomiting, signs of gallbladder problems (pain in the upper right abdomen, yellowing of skin or eyes), reduced urine output, or symptoms of liver injury

• Do not use these medications if pregnant or planning pregnancy—discuss contraception with your healthcare provider

• Inform all healthcare professionals about weight loss medication use, especially before surgery or when prescribed new medications

• Report suspected adverse drug reactions to the MHRA Yellow Card Scheme (online at yellowcard.mhra.gov.uk or via the Yellow Card app) to contribute to ongoing safety monitoring

Weight loss medications require ongoing medical supervision. Patients should have regular follow-up appointments to monitor effectiveness, manage side effects, and assess whether continued treatment is appropriate. GLP-1 treatment should be stopped if insufficient weight loss is achieved (typically defined as less than 5% weight loss after 12 weeks at maintenance dose for liraglutide, or as per semaglutide SmPC guidance) or if side effects are intolerable. Orlistat should be reviewed at 12 weeks and discontinued if adequate weight loss has not been achieved.

Frequently Asked Questions